MEDICATION SAFETY
FDA recently warned that dronedarone (Multaq, Sanofi-Aventis) increases the risk of serious cardiovascular events–including death–when used by patients in permanent atrial fibrillation. » More |
|
FDA revised the dose limitation for simvastatin from 10 mg to 20 mg when it is co-administered with the cardiac drug amiodarone and the drug labels for Zocor and generics as well as Vytorin have been updated to reflect this correction, according to a Drug Safety Communication issued by the agency on December 15, 2011. » More |
Editor's Pick
Treatment of rheumatoid arthritis
A review of recommendations and emerging therapy for rheumatoid arthritis.
» Click here. |
CONTINUING EDUCATION
Successful collaborative relationships with physicians and other healthcare providers greatly enhance patient care. Knowing how to build those relationships is job 1. Earn up to 2 CPE credits. » Click here to login and take the exams. |
REMS
Pharmacies and prescribers will be able to enroll in a single shared Risk Evaluation and Mitigation Strategy for the transmucosal immediate-release fentanyl products beginning in March. » More |
CLINICAL NEWS
Extended-release niacin demonstrated no clinical benefit as an add-on therapy to statins in patients with established coronary heart disease and low levels of baseline HDL cholesterol, according to the results of a study published December 15, 2011, in the New England Journal of Medicine. » More |
|
Daily vitamin D or calcium supplementation has no impact on mortality, vascular disease, cancer mortality, or cancer incidence, according to the results of a study published online November 23, 2011, in the Journal of Clinical Endocrinology & Metabolism. » More |
|
The recurrence of Clostridium difficile infection is less frequent with fidaxomicin than with vancomycin, according to a new review of the effectiveness of C. difficile treatments. » More |
FDA NEW INDICATION
FDA has approved Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] (Prevnar 13, Pfizer) as a single dose for use in adults aged 50 years and older.
» More |
Survey
1) Immediately remove all aliskiren-based products from formulary and recommend switching patients to alternative anti-hypertensive medications
2) Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of ALL patients on an aliskiren product
3) Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of only ‘high-risk’ patients on such an aliskiren combo
4) Implement new prior authorization and/or new contingent therapy edits on aliskiren products to minimize new patient starts on such combinations
5) Do nothing for the time-being until more definitive direction is provided from FDA
Respond here and see what your colleagues think too.
Want to see the results of our last survey regarding chronic atrial fibrillation management?
Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
